Skip to main content

Table 2 Intake of antiherpetic drugs during follow-up. ‶Echantillon Généraliste des Bénéficiaires.″ 2009–2017

From: Antiherpetic drugs: a potential way to prevent Alzheimer’s disease?

  Study sample N=68291, N (%) Systemic antiherpetic drugs (N=6642), N (%)
Antiherpetic drugs 9650 (14.13)  
Systemic antiherpetic drugs 6642 (9.73) 6642 (100.00)
 J05AB01 Aciclovir 1101 (1.61) 1101 (16.58)
 J05AB09 Famciclovir 26 (0.04) 26 (0.39)
 J05AB11 Valaciclovir 5879 (8.61) 5879 (88.51)
 J05AB14 Valganciclovir 17 (0.02) 17 (0.26)
 Number of deliveries during follow-up, median [IQR], p90 and p95   1 [12], 7 and 16
 Number of deliveries per year of follow-up, median [IQR], p90 and p95   0.12 [0.110.33], 1 and 2.3
 ≥ 2 deliveries per year of follow-up 169 (0.25) 169 (2.54)
Nonsystemic antiherpetic drugs 5375 (7.87) 2367 (35.64)
Dermatological application 4903 (7.18) 2067 (31.12)
  D06BB03 Aciclovir 4903 (7.18) 2067 (31.12)
Ophthalmological application 615 (0.90) 420 (6.32)
  S01AD02 Trifluridine 93 (0.14) 39 (0.59)
  S01AD03 Aciclovir 341 (0.50) 267 (4.02)
  S01AD09 Ganciclovir 247 (0.36) 167 (2.51)
  1. Abbreviations: IQR interquartile range, p90 90th percentile, p95 95th percentile